No Data
No Data
Mesoblast Set To File BLA For Ryoncil With FDA Next Week
Mesoblast to Submit FDA Application for Ryoncil in Treating Pediatric GVHD
Mesoblast Limited (NASDAQ:MESO, ASX:MSB))))), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for ap
High Insider Ownership Growth Stocks On The ASX In June 2024
Cantor Fitzgerald Reiterates Overweight on Mesoblast
Cantor Fitzgerald analyst Louise Chen reiterates Mesoblast (NASDAQ:MESO) with a Overweight.
Mesoblast Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/04/2024 — Cantor Fitzgerald Reiterates → Overweight 09/21/2023 133.52% Cantor Fitzgerald → $17 Reitera
Mesoblast Targets FDA Approval With Ryoncil